AIM ImmunoTech Inc. — Q2 2020 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2020. Amounts below are in U.S. dollars; financial statement figures are converted from thousands to millions unless otherwise stated.
Business context
AIM is a clinical-stage immunopharmaceutical company developing Ampligen (rintatolimod) for cancer, viral diseases and immune disorders, and Alferon N Injection. Ampligen was not FDA-approved or marketed in the United States. It was approved in Argentina for severe chronic fatigue syndrome, but commercial launch still depended on final product inspection and release testing. Alferon’s U.S. commercial production remained on hold pending manufacturing modernization and FDA requirements.
Financial performance and liquidity
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Revenue | $0.040m | $0.029m | $0.085m | $0.029m |
| Operating loss | $3.340m | $3.224m | $6.648m | $6.150m |
| Net loss | $3.370m | $2.036m | $7.160m | $5.393m |
| Basic and diluted loss per share | $0.11 | $1.07 | $0.19 | $3.53 |
Revenue was generated through Ampligen’s cost-recovery programs. Revenue remains minimal relative to operating costs, so conventional operating margins are not meaningful. Q2 costs and expenses were $3.380m, including $1.463m of R&D and $1.717m of general and administrative expense.
At June 30, cash and cash equivalents were $33.908m, with marketable securities of $6.401m, for cash and investments of approximately $40.309m. Current assets were $35.165m and current liabilities $0.833m. Total assets were $50.123m and stockholders’ equity $46.992m. Notes payable were paid off during the quarter; the remaining financing obligation related to the sale-leaseback was $2.214m, including its current portion.
For the first half, operating activities used $4.525m of cash; investing activities provided $0.601m; and financing activities provided $36.362m. Financing proceeds included approximately $32.878m from common-stock sales under the Maxim equity distribution agreement, as well as warrant exercises. Cash increased by $32.438m from year-end 2019.
Changes versus comparable periods
- Six-month net loss increased $1.767m, or 33%, from 2019; Q2 net loss increased $1.334m, or 66%.
- Six-month R&D rose $0.319m, mainly reflecting Ampligen manufacturing, stability and compliance costs. Six-month G&A increased $0.277m, including higher compensation and professional fees.
- Warrant remeasurement shifted from a $1.039m gain in the first half of 2019 to a $0.150m loss in 2020, a non-cash item. A $0.260m litigation settlement recorded in 2019 did not recur.
- Common shares outstanding increased from 10.387m at December 31, 2019 to 34.251m at June 30, 2020, reflecting equity sales and warrant exercises.
Outlook, risks and unusual items
- Management was pursuing development and commercialization partnerships and expanding Ampligen research into COVID-19, including a Roswell Park Phase 1/2a study of Ampligen with interferon in cancer patients with COVID-19. The filing also described preclinical research collaborations and an intranasal prophylaxis trial plan; the latter was subject to FDA IND authorization.
- After quarter-end, AIM engaged Amarex for the proposed intranasal COVID-19 trial. The company estimated costs of about $514,000 for Phase I, $650,000 for Phase II and an additional $4.5m in trial costs, subject to regulatory authorization and execution.
- Management stated that the pandemic’s effect on operations, liquidity and capital resources could not yet be reasonably estimated. COVID-19 could delay enrollment, trial sites, regulatory decisions, supply shipments and reporting.
- Ampligen’s U.S. NDA for chronic fatigue syndrome had received an FDA Complete Response Letter in 2013; additional clinical and nonclinical work could be required. Management gave no assurance of approval, successful trials, commercialization or future funding.
- Alferon production had no definitive restart timetable. Resumption required manufacturing work, FDA inspection and release approval; failure to obtain approvals could materially adversely affect operations.
- AIM disclosed a pending contract dispute with BioLife. AIM sought damages not yet determined; BioLife counterclaimed for $96,676. The filing also reported that court scheduling was affected by pandemic-related closures.
- The company reported no off-balance-sheet arrangements and no material change in internal control over financial reporting; management considered disclosure controls effective at June 30, 2020.
Important facts for investors to verify
- Whether the Argentina Ampligen launch received final ANMAT inspection and release approval, and whether commercial sales began.
- FDA authorization, trial initiation, enrollment, funding and results for the proposed intranasal COVID-19 study and the Roswell Park study.
- Actual cash use and remaining liquidity relative to clinical, manufacturing and operating commitments, including the estimated COVID-19 trial costs.
- Progress and cost of Alferon manufacturing modernization, required FDA inspection and the timing and likelihood of renewed commercial production.
- Equity issuance, warrant exercises and resulting dilution; reconcile the reported share-count and weighted-average-share figures with subsequent filings.
- The filing’s cash-flow comparison is inconsistent: the cash-flow statement reports first-half 2019 operating cash use of $4.234m, while MD&A gives $4.324m in one passage and $4.525m as the 2020 figure. Confirm the correct comparative amount.